Clinical Research Protocols:
Clinical Research Protocols in Screening
Compiled by Margaret Gross-King, RN, MS, OCN
Clinical Research Manager, H. Lee Moffitt Cancer Center & Research Institute
For more information on
these protocols, please call PDQ, a service of the National Cancer Institute,
at 1-800-4-CANCER.
(Editor's note: A search
of PDQ, the National Cancer Institute data base of clinical research protocols,
found the following protocols related to screening. Other protocols focusing
on issues of chemoprevention are not included here. For more information on
clinical research protocols relating to prevention, please contact PDQ directly.)
MDADM89089, NCIC890005,
NCIP900010 Study of the Utility of Mucosal BUDR Uptake and Proliferating
Cell Nuclear Antigen in Predicting Colonic Adenomatous Polyp Recurrence
(Summary Last Modified 11/92)
Chairman: Rodger J. Winn,
M.D. Anderson Cancer Center, Houston, Tex. Lead Organization: M.D. Anderson.
Acceptable age range: 18 to 65
PLCO1, NCIP930050
A 16Year Randomized Screening Trial for Prostate, Lung, Colorectal and Ovarian
Cancer PLCO Trial (Summary Last Modified 05/95)
Chairman: John K. Gohagan,
National Cancer Institute, National Institutes of Health, Bethesda, Md. Lead
Organization: Early Detection Branch, National Cancer Institute. Acceptable
age range: 60 to 74
E5593, NCIP950067
Early Detection of Second Primary Lung Cancer by Sputum Cytology Immunostaining
in Patients With Curatively Resected Stage I Nonsmall Cell Lung Cancer (Summary
Last Modified 08/95)
Chairman: John C. Ruckdeschel,
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Fla. Lead Organization:
Eastern Cooperative Oncology Group. Acceptable age range: no age specified
NCI92C0052 Pilot
Study of Neuroendrocine Peptide Levels as Potential Predictors of Second
Lung Cancer After Surgical Resection With Curative Intent in Stage I/II
Nonsmall Cell Lung Cancer (Summary Last Modified 09.95)
Chairman: Michael J. Kelley,
National Cancer Institute, National Institutes of Health. Lead Organization:
Clinical Oncology Program, National Cancer Institute. Acceptable age range:
18 and over
NCI94C0042 Identification
of Men Under Age 55 With a Genetic Predisposition to Prostate Cancer
(Summary Last Modified 04/94)
Chairman: William M. Linehan,
National Cancer Institute, National Institutes of Health. Lead Organization:
Clinical Oncology Program, National Cancer Institute. Acceptable age range:
under 55
Back
to Cancer Control Journal Volume 2 Number 6